Tags : Ventana ALK (D5F3) CDx Assay


Roche’s Ventana ALK (D5F3) CDx Assay Receives the US FDA’s

Shots: The US FDA has granted approval of Ventana ALK (D5F3) as a CDx assay to identify ALK+ NSCLC patients eligible for treatment with Pfizer’s drug Lorbrena (lorlatinib) The label expansion approval strengthens Roche’s commitment to personalized healthcare by providing lung cancer patients with access to more treatment options The Ventana ALK (D5F3) CDx assay […]Read More